Glycostem
Business Services · Netherlands · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Kloosterstraat 9, Oss, North Brabant, 53...Phone Number
+31 412211001Website
www.glycostem.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Glycostem
Founded in 2007 and headquartered in The Netherlands, Glycostem Therapeutics is focused on the development of stem cell-derived Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Glycostem your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Glycostem launches new products
Glycostem, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Glycostem has new funding data
Check out if Glycostem is spiking on competitors!
Check if Glycostem has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Glycostem recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Glycostem
Click to see if Glycostem had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Glycostem
Find 3 more new buyers
Company Profile Activity
Activity Insights
Glycostem is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Glycostem is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Glycostem.
Glycostem Tech Stack
A closer look at the technologies used by Glycostem
Glycostem News & Media
Glycostem announces new data presentation at EHA 2022 Congress highlighting early safety and clinical course of oNKord® in patients with Acute Myeloid Leukemia
OSS, Netherlands, May 13, 2022 /PRNewswire/ -- Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, today announced that an abstract on further findings of patients treated in its phase...Glycostem announces initial clinical data to be presented at 2021 ASH Annual Meeting
OSS, Netherlands, Nov. 4, 2021 /PRNewswire/ -- Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, today announced that the abstract on the initial findings of the first two patients...Dr. Kai Pinkernell, M.D. joins Glycostem's leadership team as Chief Medical Officer
OSS, Netherlands, April 1, 2021 /PRNewswire/ -- Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, today announced that Dr. Kai Pinkernell, M.D. joins Glycostem as Chief Medical...Glycostem and Ghent University sign license agreement on NK cell therapy technology
OSS, Netherlands, Dec. 17, 2020 /PRNewswire/ -- Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK) cells, and Ghent University (UGent) have signed a license agreement for an innovative NK cell...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Glycostem
Sign Up For FreeTo access detailed company insights
Founded in 2007 and headquartered in The Netherlands, Glycostem Therapeutics is focused on the development of stem cell-derived Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer.... Read More
